Search Results

You are looking at 181 - 190 of 576 items for :

  • Refine by Access: All x
Clear All
Full access

Distress Management

Jimmie C. Holland, Barbara Andersen, William S. Breitbart, Bruce Compas, Moreen M. Dudley, Stewart Fleishman, Caryl D. Fulcher, Donna B. Greenberg, Carl B. Greiner, Rev. George F. Handzo, Laura Hoofring, Paul B. Jacobsen, Sara J. Knight, Kate Learson, Michael H. Levy, Matthew J. Loscalzo, Sharon Manne, Randi McAllister-Black, Michelle B. Riba, Kristin Roper, Alan D. Valentine, Lynne I. Wagner, and Michael A. Zevon

, dramatic advances in early detection and treatment options have increased overall survival rates in patients of all ages with cancer. At the same time, these improved treatment options are also associated with substantial long-term side effects. Fatigue

Full access

Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2− Breast Cancer

included Table 1. CDK 4/6 Inhibitors neutropenia, anemia, and fatigue. No cases of febrile neutropenia were observed. However, an increased rate of grade 3/4 infections and pulmonary embolism was seen in the palbociclib/letrozole arm (5% vs 0

Full access

NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy

Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke, and Sandy Srinivas

associated with these therapies could be caused by regression of capillaries around thyroid follicles. Clinical or laboratory evidence of hypothyroidism has been found in a significant proportion of patients on sunitinib and may contribute to fatigue in these

Full access

Cancer- and Chemotherapy-Induced Anemia

George M. Rodgers III, Pamela Sue Becker, Morey Blinder, David Cella, Asher Chanan-Khan, Charles Cleeland, Peter F. Coccia, Benjamin Djulbegovic, Jeffrey A. Gilreath, Eric H. Kraut, Ursula A. Matulonis, Michael M. Millenson, Denise Reinke, Joseph Rosenthal, Rowena N. Schwartz, Gerald Soff, Richard S. Stein, Gordana Vlahovic, and Alva B. Weir III

symptoms; comorbidities; family history; and exposure to antineoplastic drugs and radiation. Common complaints are syncope, exercise dyspnea, headache, vertigo, chest pain, fatigue (disruptive to work and daily activities), and abnormal menstruation in

Full access

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

Featured Updates to the NCCN Guidelines

John A. Thompson, Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew Frigault, Benjamin H. Kaffenberger, Matthew Lunning, Suzanne McGettigan, Jordan McPherson, Nisha A. Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan Oluwole, Sandip P. Patel, Nathan Pennell, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Ryan M. Weight, Alyse Johnson-Chilla, Griselda Zuccarino-Catania, and Anita Engh

, but especially if the cough is dry or is coupled with shortness of breath, it could indicate pneumonitis . Headaches can be indicative of brain metastases, but when presenting with fatigue , visual symptoms , nausea , and other symptoms, may be

Full access

Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices

Neelima Denduluri, Debra A. Patt, Yunfei Wang, Menaka Bhor, Xiaoyan Li, Anne M. Favret, Phuong Khanh Morrow, Richard L. Barron, Lina Asmar, Shanmugapriya Saravanan, Yanli Li, Jacob Garcia, and Gary H. Lyman

, such as fatigue, 45 , 46 nausea and vomiting, 47 neuropathy, 42 , 48 mucositis, 49 renal dysfunction, 20 patient request, and weight change, 22 , 27 may also lead to dose delays and reductions. Deviations from standard regimens as a result of

Full access

Determining Chemotherapy Tolerance in Older Patients With Cancer

Jerome Kim and Arti Hurria

have linked depression to hospitalizations, 6 chemotherapy toxicity, and decreased survival in older adults with cancer. 9 Studies have noted loss of independence and fatigue as leading causes of patient distress, which leads to a reduced ability to

Full access

Treatment of Non–Small Cell Lung Cancer in the Older Patient

Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III, and Arti Hurria

Fatigue Inventory has helped evaluate the fitness of older patients for cancer surgery. 13 – 15 Clinical trials are ongoing to establish more simplified, time-efficient, and validated instruments to quantify fitness for various forms of therapy. Recent

Full access

Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz

) The most common grade 1/2 toxicities with FOLFOX were fatigue (58%), nausea (32%), and neutropenia (25%). The most common grade 3 toxicities were diarrhea (4%), fatigue (1%), nausea (1%), and neutropenia (1%). These were managed with dose reductions

Full access

A Review of the Symptomatic Management of Malignant Gliomas in Adults

Umang Shah and Tara Morrison

delayed effects of treatment can help physicians and patients make informed choices bearing on survival and QOL. Several studies in patients with malignant gliomas showed that fatigue is the most frequently reported and troublesome of all symptoms. It is